Kite Pharma’s CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel – AJMC.com Managed Markets Network
|
Kite Pharma’s CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel
AJMC.com Managed Markets Network The FDA has given the go-ahead for a second chimeric antigen receptor (CAR) T cell therapy: axicabtagene ciloleucel (Yescarta), developed by Kite Pharma, which was recently acquired by Gilead Sciences, has been approved to treat adult patients with … |
|
‘Stings & Things’: Noted Allergist Discusses Venom Immunotherapy at WRNMMC
Pentagram Golden provided the Walter Reed Bethesda allergists, pediatricians and internal medicine primary care providers with clinical and research information pertaining to measures to avoid getting stung, risks for severity and dosing for venom immunotherapy … |
Forbes |
PBS’s Documentary ‘The Gene Doctors’ Arrives Amid A Gene – Forbes
Forbes A new PBS film educates viewers about gene therapy at a time when the once controversial field of research is starting to bear fruit. First-of-Its-Kind Gene Therapy Could Treat BlindnessHealthline |
|
FDA Approves CAR T-Cell Therapy for Non-Hodgkin Lymphoma
www.oncnursingnews.com/ The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) for people with large B-cell lymphoma following 2 prior therapies, including for those with diffuse large B-cell lymphoma (DLBCL). It is also … FDA Approves Yescarta™, Revolutionary CAR–T Immunotherapy for Non-Hodgkin’s Lymphoma PatientsPR Newswire (press release) FDA Approves Axi-Cel for Large B-cell LymphomaTargeted Oncology |
Friedreich’s Ataxia News |
CRISPR Therapeutics Receives FARA Grant to Develop Gene Editing Therapies for Friedreich’s Ataxia
Friedreich’s Ataxia News “We believe that the combination of CRISPR’s pioneering gene-editing capabilities with Dr. Marek Napierala’s deep expertise in FA may accelerate the development of new therapies for FA,” Jennifer Farmer, FARA’s executive director, said in a press release. |